BostonGene Funding, Investors & Competitors

BostonGene has raised $200M across 2 funding rounds, most recently a $150M Series B in April 2022.

Last BostonGene funding round

$150M

Series B · Apr 2022

Cumulative funding BostonGene raised

$200M

across 2 funding rounds

Key investors in BostonGene

  • NEC
  • Japan Industrial Partners
  • Impact Investment Capital

BostonGene Overview

About BostonGene

BostonGene is a Waltham-based precision oncology company applying genomic profiling and AI analytics to match cancer patients with therapies. Launched in 2016, its TumorGMO assay sequences DNA, RNA, and proteomics from biopsies, analyzing over 50,000 tumor samples annually. BostonGene partners with hospitals like City of Hope and Dana-Farber Cancer Institute to guide treatments using FDA-approved drugs and clinical trials.


Founded

2015

HQ

United StatesBoston, MA

Status

Privately held

Customer focus

B2B

Revenue model

Services, Subscription

BostonGene Funding History

BostonGene has raised a total of $200M across 2 funding rounds.

BostonGene's first fundraising round was a $50M Series A in April 2019. The most recent completed round was a $150M Series B in April 2022.

BostonGene funding rounds

BostonGene funding rounds
DateStageInvestorsRaisedDeal Summary
Apr 2022Series BNEC (lead); Japan Industrial Partners; Impact Investment Capital$150MBostonGene is a precision oncology company headquartered in Waltham, Massachusetts, founded in 2015, that develops an AI-powered platform for molecular and immune profiling of tumors. Its core product, the Tumor Portrait test (also called Molecular Portrait Test), integrates genomic data, analytics, and machine learning to analyze tumor biology, microenvironment, and host immunity, helping oncologists identify personalized cancer therapies, predict treatment responses, and improve patient outcomes. On April 6, 2022, BostonGene closed a $150 million Series B funding round led by NEC Corporation, with participation from Impact Investment Capital and Japan Industrial Partners. The round propelled the company to unicorn status at a multi-billion dollar valuation, bringing total funding to around $200 million at that point. Proceeds are earmarked for accelerating R&D, expanding clinical and research partnerships, scaling operations, and enabling international growth, particularly in Japan and Asia via a planned joint venture with NEC leveraging its AI and infrastructure capabilities. The financing builds on prior rounds, including a Series A, and supports adoption of BostonGene's tests by U.S. academic and community oncologists. NEC's involvement aligns with its healthcare and life sciences unit under its 2025 Mid-term Management Plan, aiming to advance global clinical outcomes through AI-driven precision medicine.
Apr 2019Series ANEC (lead)$50MBostonGene Corporation, founded in 2015, is a Boston-based biomedical software company developing a precision medicine computing platform for cancer treatment, utilizing genome and transcriptome sequencing to create molecular portraits of tumors. The platform supports personalized cancer therapy by analyzing tumor profiles, microenvironment, and host immunity, with early adoption by leading U.S. cancer centers and a robust intellectual property portfolio. On April 25, 2019 (announced Tokyo) and April 24, 2019 (Boston), NEC Corporation made a US$50M Series A strategic investment in BostonGene. The proceeds supported scaling the platform, expanding development efforts, advancing collaborations, growing the team, and forming synergies with NEC's Health Tech business to enhance AI-driven cancer immunotherapy and improve patient survival and quality of life. BostonGene's leadership, including President and CEO Andrew Feinberg, highlighted the platform's transformative potential validated by early successes and market need. NEC's Osamu Fujikawa emphasized BostonGene's leadership in precision medicine innovation. This round preceded a 2022 Series B. Aggregated funding data across sources confirms $50M Series A in 2019 from NEC, with total raised reaching $200M by 2022 Series B ($150M led by NEC with Impact Investment Capital and Japan Industrial Partners).

Who has invested in BostonGene?

3 investors have backed BostonGene across its funding rounds, including NEC, Japan Industrial Partners and Impact Investment Capital.

Lead investors include NEC.


BostonGene Investors

Investors in BostonGene by funding rounds participated
InvestorHQRoundsRoleFirst check
NECJapanTokyo2LeadApr 2019

This data is available for Pro users. Sign up to see all 3 BostonGene investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

BostonGene Competitors

BostonGene competitors include listed companies like IQVIA, ICON plc and Privia Health, and private ones like Hippocratic AI, Innovaccer and NantHealth.

Public and private companies comparable to BostonGene
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
IQVIAUnited StatesUnited StatesPublicly listed$16B$3.4B$44B3.4x
ICON plcUnited StatesUnited StatesPublicly listed$8.3B$816M$13B1.9x
Hippocratic AIUnited StatesSan Francisco, CAPrivate--$3.5B-
InnovaccerUnited StatesSan Francisco, CAPrivate$250M-$3.5B13.8x
Privia HealthUnited StatesUnited StatesPublicly listed$2.1B$44M$2.6B0.9x
NantHealthUnited StatesLos Angeles, CAPrivate$58M-$2B-

BostonGene Public Comps

BostonGene is still privately-owned, but its public comps include IQVIA, Veeva, IDEXX Laboratories, Roper Technologies, GE HealthCare, Revvity, Solventum, Tempus AI, ICON plc and Pro Medicus.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
IQVIA$16B$3.4B3.6x3.4x17.2x14.8x
Veeva$3.2B$965M11.1x10.2x36.9x22.4x
IDEXX Laboratories$4.3B$1.5B9.5x8.9x27.1x24.9x
Roper Technologies$7.9B$3.2B6.1x5.7x15.2x14.6x
GE HealthCare$21B$3.7B1.8x1.8x10.1x10.0x
Revvity$2.9B$735M6.5x6.6x25.4x21.0x
Solventum$8.3B$2.5B2.4x2.4x7.8x8.9x
Tempus AI$1.3B($131M)12.0x10.1x(116.0x)346.0x

This data is available for Pro users. Sign up to see all BostonGene competitors and their valuation data.

Start Free Trial

Common questions about BostonGene

When was BostonGene founded?BostonGene was founded in 2015.
Where is BostonGene headquartered?BostonGene is headquartered in Boston, MA, United States.
Is BostonGene publicly listed?No, BostonGene is a private, VC-backed company.
How much funding has BostonGene raised?BostonGene has raised $200M across 2 funding rounds.
What was BostonGene's last funding round?BostonGene's last funding round was a $150M Series B in April 2022, led by NEC.
Who are BostonGene's investors?BostonGene's investors include NEC, Japan Industrial Partners and Impact Investment Capital.
Which companies are comparable to BostonGene?Companies comparable to BostonGene include IQVIA, ICON plc, Hippocratic AI, Innovaccer, Privia Health and NantHealth.

See companies similar to BostonGene

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial